Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCA033989 Monotherapy or in Combination With Ruxolitinib in Myeloproliferative Neoplasms
NCT06034002Phase 1Recruiting
- Sponsor
- Incyte
- Start
- Dec 2023
- Primary completion
- Oct 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of inca033989 in myelofibrosis (MF) and essential thrombocythemia (ET) (7 arms), sponsored by Incyte. Primary endpoints: Number of participants with Dose Limiting Toxicities at 28 days and Number of participants with Treatment-emergent Adverse Events at 60 days. Started Dec 2023; status: recruiting.
02
Drugs
inca033989
03
Conditions
myelofibrosis (MF)essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT06034002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06034002.